Novartis pelacarsen trial miss may be cushioned by investor skepticism
Citi says Novartis’ experimental pelacarsen missed the target in a late-stage clinical trial, but the share-price hit could be mitigated by investor skepticism about the study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.